The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“The Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011; Chappell et al., 2012)was used to assess and classify reported suicidal behavior.”
MethodA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“hyperprolactinemia (and associated sexual effects), sedation, weight gain and other metabolic effects (De Hert et al., 2012; Leucht et al., 2013).”
BackgroundSchizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality
McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Salomon, J. A., Vos, T., Hogan, D. R., Gagnon, M., Naghavi, M., Mokdad, A., Begum, N., Shah, R., Karyana, M., Kosen, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61680-8 · Cited by 1,322
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · PubMed · Cited by 1,168
Cited by
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
“…on previous research efforts by enrolling patients from up to three prior phase III studies, including the aforementioned investigation by Fleischhacker et al 8 and two 6-week acute efficacy trials, 4,5 in addition to patients who had never previously participated in a brexpiprazole study.”
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12752 · Cited by 107
Fleischhacker, W. W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R. D., Carson, W. H., Sanchez, R., Nyilas, M., & Weiller, E. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw076 · Cited by 88
Self-citationCitrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Forbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52
“The safety and tolerability results of the present study are generally similar to those observed in prior short- and longterm studies of brexpiprazole in schizophrenia (Correll et al., 2015; Kane et al., 2015; Fleischhacker et al., 2017).”
BackgroundMethodResultInfluentialSelf-citationEffect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
Ivkovic, J., Lindsten, A., George, V., Eriksson, H., & Hobart, M. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000979 · Cited by 41
Self-citationAntipsychotic Dose in Acute Schizophrenia: A Meta-analysis
Takeuchi, H., MacKenzie, N. E., Samaroo, D., Agid, O., Remington, G., & Leucht, S. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa063 · Cited by 39
Ishigooka, J., Iwashita, S., & Tadori, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12654 · Cited by 35
Brexpiprazole: A Review in Schizophrenia
Garnock-Jones, K. P. (2016) · CNS Drugs · doi:10.1007/s40263-016-0325-8 · Cited by 30
“25 mg/day in VECTOR were included for exploratory purposes (the studies were not powered for statistical comparisons between these groups and placebo recipients) [16, 17] and the 0.”
BackgroundInfluentialNewcomer, J. W., Eriksson, H., Zhang, P., Weiller, E., & Weiss, C. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1498779 · Cited by 25
Self-citationMarkovic, M., Gallipani, A., Patel, K. H., & Maroney, M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028016678262 · Cited by 22
Aigbogun, M. S., Liu, S., Kamat, S. A., Sapin, C., Duhig, A. M., & Citrome, L. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s160252 · Cited by 18
“The efficacy of brexpiprazole in schizophrenia was demonstrated in two 6-week, randomized, double-blind, placebo-controlled, fixed-dose clinical trials.(14,15) Brexpiprazole has demonstrated a low incidence of sedating or activating AEs, a low rate of long-term metabolic effects, and moderate weight gain.”
Correll, C. U., Shi, L., Weiss, C., Hobart, M., Eramo, A., Duffy, R. A., Weiller, E., & Baker, R. A. (2019) · CNS Spectrums · doi:10.1017/s1092852918001086 · Cited by 16
“Due to the design of the acute studies for regulatory approval, in which patients were washed out from prior antipsychotics before brexpiprazole was initiated, these studies generated no data on switching strategies or outcomes.(11,12) In contrast, the brexpiprazole maintenance study included a 1–4 week conversion pha…”
ResultSelf-citationBrubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s501207 · Cited by 7
Metadata
- Authors
- Kane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 164
- Issue
- 1-3
- Pages
- 127-135
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W1990121386
- Cited by
- 325
- References
- 34
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.